This page is updated frequently with new Monoclonal-related patent applications.
|High-throughput single cell sorting using microbubble well arrays|
The present invention provides a microfabricated device and methods for high throughput single cell screening of a heterogeneous population. The present invention is partly based upon but not limited to sorting by monitoring cell secreted factors that accumulate in time (hours, days, weeks) as cells are cultured in the microbubble well niche the architecture of which facilitate the accumulation.
Nidus Biosciences, Llc
|Humanized monoclonal antibodies and methodsof use|
The present invention comprises a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene vh1-69. This antibody is derived from mab g6 and recognizes the same epitope.
Dana-farber Cancer Institute, Inc.
|Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells|
This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (fra) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to fra-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors.
|Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function|
Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.
St. Jude Children's Research Hospital
|Methods of evaluating quality of a chromatography media which binds anti-a or anti-b antibodies|
Embodiments described herein relate to methods of evaluating quality of a chromatography media for removal of anti-a or anti-b antibodies from a sample, where the methods employ use of purified monoclonal igm-a and igm-b antibodies.. .
Merck Patent Gmbh
|Enhancing serological assays via fusion proteins|
A serological assay with an improved linear range of detection is disclosed using a fusion protein system, such as an anti-cytokine/cytokine fusion protein (acyf) system, for evaluating immune responses. Also disclosed are related compositions, fusion proteins, expression vectors, monoclonal antibodies, and kits for practicing the assay method of the present invention..
|Methods and materials for the detection of dengue virus infection|
The present invention provides monoclonal antibodies that are specific for the dengue non-structural glycoprotein ns1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including elisa and lateral flow assays, that employ the disclosed antibodies for the early detection of dengue virus infection. Diagnostic kits for the detection of dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies..
Inbios International, Inc.
|High affinity and aggregatively stable antibodies on the basis of variable domains vl and a derivative vhh|
The monoclonal igg-type antibodies were suggested comprising variable domains represented by a combination of vhh-derivative with a variable domain of the light chain vl. Said antibodies can comprise amino acid substitutions at positions 44 and 45 (kabat numbering) or combinations thereof.
Closed Joint Stock Company "biocad"
|Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis|
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular
|Monoclonal antibodies against her2 epitope and methods of use thereof|
This invention provides fully human monoclonal antibodies that recognize her2. The invention further provides methods of using such monoclonal antibodies in a variety of therapeutic, diagnostic, and prophylactic indications..
Mersana Therapeutics, Inc.
Production of hersintuzumab: a new humanized antibody against her2 for cancer treatment
A monoclonal anti-her2 antibody is mutated on complementarity determining regions (cdrs) and framework regions. The vh domain of the antibody includes a portion of the amino acid sequence as seq id no: 1.
Monoclonal antibody against human prpc and use thereof
A monoclonal antibody against human prpc protein capable of reducing the expression level of transcription factor twist1 in a targeting mode and inducing macrophage and nk cells to target to rectal cancer tumor cells. The combined drug therapy with the antibody and cetuximab also exhibits inhibitory effect on tumor better than administration of the antibody or cetuximab alone..
Institute Of Zoology, Chinese Academy Of Sciences
Monoclonal antibodies that neutralize a norovirus
monoclonal neutralizing antibodies are disclosed that specifically bind to a norovirus. In some embodiments, the norovirus is a genogroup ii norovirus or a genogroup ii norovirus.
The United States Of America, As Represented By The Secretary, Department Of Health And Human
Erbb2 signaling and nerve regeneration
Use of an inhibitor of the erbb2 receptor for treatment or repair of nerves and/or nerve tissues is provided. The inhibitor includes an antibody, in particular, a monoclonal antibody, for example, herceptin.
The Hospital For Sick Children
Monoclonal antibodies for treatment of cancer
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing gt468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.. .
Johannes Gutenberg-universität Mainz
Anti-despr monoclonal antibody targeted therapy and imaging for cancer and stroke
Provided herein are novel compositions comprising anti-despr antibodies and fragments thereof derived from 6g8g7 and 7c5b2 anti-despr variant antibodies, including fully human, composite engineered human, humanized, monoclonal, and polyclonal anti-despr antibodies and fragments thereof, and methods of their use in a variety of therapeutic applications. The compositions comprising the anti-despr antibodies and fragments thereof described herein are useful in diagnostic and imaging methods, such as despr-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo non-invasive imaging and/or assessments..
Trustees Of Boston University
Human antibodies that bind cd22 and uses thereof
The present disclosure provides isolated monoclonal antibodies that specifically bind to cd22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided.
E. R. Squibb & Sons, L.l.c.
Ultrafiltration unit for continuous buffer or medium exchange from a protein solution
The invention relates to an ultrafiltration unit for continuous buffer or medium exchange, a method for continuous buffer or medium exchange in the ultrafiltration unit, and a plant in particular for (semi)continuous production of biopharmaceutical and biological macromolecular products in particular, such as proteins, e.g. monoclonal antibodies and vaccines, comprising the ultrafiltration unit according to the invention..
Cancer therapy using beta glucan and antibodies
The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble beta (1,3; 1,6) glucan (nsg) enhances the tumoricidal activity of the innate immune system by binding to the c3 complement protein receptor cr3.
University Of Louisville Research Foundation, Inc.
Detection methods employing hcv core lipid and dna binding domain monoclonal antibodies
The present disclosure provides detection methods employing hcv core lipid binding domain and dna binding domain monoclonal antibodies or antibody fragments. In certain embodiments, the lipid binding domain monoclonal antibody or antibody fragment recognizes an epitope in amino acids 141 to 161 of hcv core protein and the dna binding domain antibody or antibody fragment recognizes an epitope in amino acids 95-123 (e.g., in amino acids 99-117) of hcv core protein..
Icahn School Of Medicine At Mount Sinai
Detection methods employing hcv core lipid and dna binding domain monoclonal antibodies
The present disclosure provides detection methods employing hcv core lipid binding domain and dna binding domain monoclonal antibodies. In certain embodiments, the lipid binding domain monoclonal antibody recognizes an epitope in amino acids 141 to 161 of hcv core protein..
Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human igf-1r and human erbb3. Exemplary antibodies inhibit signal transduction through either or both of igf-1r and erbb3.
Merrimack Pharmaceuticals, Inc.
Method of providing monoclonal auto-antibodies with desired specificity
Provided are novel binding molecules of human origin, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize antigens such as native endogenous proteins associated with, e.g., immune response, autoimmune disorders, inflammatory diseases, metabolic disorders, vascular function, neurodegenerative diseases or tumors. More particularly, a human auto-immunosome and corresponding monoclonal antibody reservoir are provided.
The present invention relates to a method for removal of large contaminants, such as virus, in a chromatographic process for purification of a target molecule, preferably monoclonal antibodies, mabs, by using a specifically designed chromatographic bead having a thin outer layer and a core functionalized with a ligand adsorbing the mabs or parts thereof.. .
Ge Healthcare Bioprocess R&d Ab
Use of anti-ccr5 antibodies in graft versus host disease
This composition and method provides for a method for reducing gvhd in a human subject which comprises administering to the subject at a predefined interval effective gvhd-reducing doses of (a) a humanized antibody designated pro 140, or of (b) an anti-ccr5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of gvhd.
Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
Provided are transgenic non-human animals, in whose genome the coding sequence of one of the endogenous immunoglobulin cγ constant regions is replaced by a human immunoglobulin cε constant regions coding sequence. One preferred transgenic animal is a mouse, in whose genome the cγ1 constant regions are replaced by human immunoglobulin cε constant regions and the cκ constant region is replaced by human immunoglobulin cκ constant region.
Allermabs Co. Ltd.
Hybridoma cell lines (my-c-cc0c2-259-1 a4) and use thereof for producing a monoclonal antibody against human cardiac myosin binding protein c (c-protein, mybpc3, cmybp-c or my-c)
monoclonal antibodies, which can be produced in vitro, against cardiac epitopes of the human my-c are produced by generating myeloma cell clones that produce such specific antibodies having epitope specificity. These monoclonal antibodies allow, among other things, the creation of an enzyme-linked immunosorbent assay (elisa) for the specific, cross-reactivity-free quantitative determination of my-c in serum, plasma, whole blood or other body fluid.
Martin- Luther-universitaet Halle-wittenberg
Humanized monoclonal antibodies and methods of use
The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope.
The Brigham And Women's Hospital
Compositions and methods for treating fatty tissue buildup
The present disclosure is directed to the treatment of diseases or conditions involving the buildup of fatty tissues, such as obesity, metabolic syndrome, type ii diabetes, etc. A composition containing a monoclonal antibody directed against gastric inhibitory polypeptide is administered.
The Metrohealth System
Use of il-31 monoclonal antibodies for treating atopic dermatitis
The present invention relates to methods of treating pruritic diseases, including but not limited to contact dermatitis, atopic dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous t cell lymphoma, bullous pemphigoid, alopecia wereata, vitiligo, acne rosacea, prurigo nodularis, scleroderma, herpes simplex virus, or combination thereof by administering il-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies..
Enrichment and characterization of human corneal endothelial cells (hcenc) with novel monoclonal antibody
This invention refers to an antibody or an antigen binding portion thereof, that binds specifically to human corneal endothelial cells (hcencs), wherein the target of the monoclonal antibody, or antigen binding portion thereof, is essentially cell surface-expressed peroxiredoxin-6 (prdx6), as well as to methods for determining suitability of a cell sample for corneal transplantation, for quantitative enrichment of human corneal endothelial cells from a mixture of cells, and for isolating human corneal en dothelial cells from a mixture of cell.. .
Singapore Health Services Pte Ltd
Antibodies for the prevention or the treatment of bleeding episodes
The invention relates to an isolated monoclonal antibody that specifically binds to the d4 domain of vwf, competes for binding to vwf d4 domain with adamts13 and partially inhibits adamts 13 -mediated degradation of vwf. More particularly, the invention relates to an isolated monoclonal antibody comprising a heavy chain wherein the variable domain comprises at least one cdr having a sequence selected from the group consisting of seq id no: 3 for h-cdr1, seq id no: 4 for h-cdr2 and seq id no: 5 for h-cdr3 and a light chain wherein the variable domain comprises at least one cdr having a sequence selected from the group consisting of seq id no: 7 for l-cdr1, seq id no: 8 for l-cdr2 and seq id no: 9 for l-cdr3.
UniversitÉ De Droit Et De La SantÉ De Lille 2
Sp35 antibodies and uses thereof
Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction.
Biogen Ma Inc.
Anti-human il-21 antibodies
monoclonal antibodies are identified that bind the il-21 protein. These antibodies are used to identify regions of the il-21 protein to where binding neutralizes il-21 activity.
Use of annexin a3 as a diagnostic and prognostic biomarker and therapeutic target for treating hepatocellular carcinoma
Annexin a3 (anax3) is utilized as a biomarker for the diagnosis and prognosis of hepatocellular carcinoma (hcc) and the utilization of a monoclonal antibody against anxa3 or antisense polynucleotide against anxa3 mrna for the suppression or treatment of hcc, alone or in combination with other hcc treatment. Monoclonal antibody against anxa3 can be administered for the suppression of tumor growth, metastasis, and chemoresistance..
The University Of Hong Kong